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Abstract 
Psoriasis is a chronic inflammatory skin condition affecting around 2% of the 
population. IL-36γ is a member of the IL-1 family of cytokines and has emerged as a 
pivotal cytokine in psoriasis pathophysiology. The mTOR pathway serves as a key 
integrator of a wide range of environmental cues, and functions as a central 
regulator of cellular processes involved with growth and repair.  
Inhibitors of mTOR have been successfully used in the treatment of several immune 
mediated conditions, however have been relatively unsuccessful in psoriasis. It has 
not been studied how mTOR inhibition affects the contribution of stromal cells to 
psoriasis.  
We assessed signal transduction downstream of IL-36γ, in primary dermal 
fibroblasts, with a particular focus on the mTOR axis, and identified a negative role 
in AKT activation, which could be attributed to feedback loops involved in mTOR 
signalling. It was demonstrated that NFκB is necessary for cytokine induction by IL-
36γ.  
We established that mTORC1 negatively regulated cytokine induction, through 
treatment with rapamycin. However, we were unable to demonstrate a clear 
reciprocal effect from the upregulation of mTOR via RNA interference.  
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1. Introduction 
1.1 Psoriasis Background 
1.1.1 Clinical Presentations of Psoriasis 
 
Psoriasis is an immune-mediated, chronic inflammatory skin condition affecting 
around 2% of the population (Feldman & Pearce 2008). Psoriasis vulgaris (a.k.a. 
chronic plaque psoriasis) is the most common form of psoriasis, representing 
around 90% of psoriasis patients, and is understandably the best-researched. 
Clinically, it typically presents as well demarcated, erythematous plaques with 
silvery-white dry scaling, and classically has a distribution forming predominantly on 
extensor surfaces such as elbows and knees, however, scalp, ears, and the lower 
back are also commonly involved. (Kim et al. 2017) 
 
Psoriasis is however a varied disease, and multiple other patterns of psoriasis exist. 
Examples include flexural psoriasis, which mainly affects axillary, perineal and 
inframammary regions, and although well demarcated, the erythematous lesions 
lack the scale that is associated with psoriasis vulgaris (Syed & Khachemoune 2011). 
Guttate psoriasis is classically post-infective, occurring after group B streptococcus 
infection of the upper respiratory tract and results in many droplet shaped lesions 
in centripetal distribution (Kim et al. 2017). Although usually a relatively benign 
condition, when psoriatic lesions have total or near-total involvement, it becomes 
known as erythrodermic psoriasis, which can profoundly disrupt the homeostatic 
capabilities of the skin, leading to hypothermia, metabolic dysregulation, and high 
output cardiac failure (Singh et al. 2016). Generalised pustular psoriasis is a rare, 
potentially life-threatening disease, in which the patient is systemically unwell and 
covered in sterile pustules which often coalesce, forming sheets. (Langley et al. 
2005) 
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1.1.2 Systemic effects of Psoriasis  
 
Psoriasis is a systemic illness and has non-cutaneous manifestations, with around 
30% of patients developing psoriatic arthritis (Boehncke & Schön 2015). Like 
psoriasis, psoriatic arthritis is a largely heterogeneous disease which commonly 
presents as an asymmetrical oligoarthritis of smaller joints, however there are 
many other distributions, affecting both peripheral joints, and the spine. Arthritis 
mutilans is a severe deforming arthritis and predominantly occurs in individuals 
with psoriatic arthritis. Psoriatic arthritis and psoriasis have a significant degree of 
overlap in pathways driving disease pathology, specifically the central roles of 
tumour necrosis factor α (TNFα) and the interleukin-23/17 (IL-23/IL-17)  axis, which 
is reflected in the shared therapeutic arsenal targeting these pathways (Kim et al. 
2017). 
 
Extracutaneous effects extend beyond arthropathies, with psoriatic disease being 
linked to increased cardiovascular risk, obesity, hypertension, and impaired insulin 
sensitivity (Hu & Lan 2017). Extensive psychosocial impacts accompany psoriatic 
disease and it has been shown to result in stigmatisation, poor self-esteem, 
increased stress, reduced social functioning, impaired relationships and increased 
incidence of depression (Fried et al. 1995) 
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1.1.3 Genetic and environmental risk factors for 
psoriasis 
 
As a multifactorial disease, psoriasis is caused by interplay between both heritable 
and environmental risks. Multiple susceptibility loci have been described for 
psoriasis. Accounting for around 50% of disease heritability is Psoriasis 
Susceptibility Gene 1 (PSORS1), a 200 kb segment of the major histocompatibility 
complex on chromosome 6p21.3. HLA-Cw6 is most likely the primary risk allele 
(Trembath et al. 1997). Variations in multiple other loci have been identified, 
predominantly with roles in both innate and adaptive immunity, specifically nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB), interferon signalling 
and the IL-23/Th17 axis (Ghoreschi 2013). Well documented triggers for psoriasis 
include mechanical trauma to the skin (as described by the Koebner Phenomenon), 
stress, infection and certain classes of drugs such as lithium and β-blockers 
(Mahajan & Handa 2013). 
 
 
 
 
 
 
 
 
12 
 
1.2 Pathophysiology of Psoriasis 
1.2.1 Hallmarks of Psoriasis  
 
There are several well-categorised histological hallmarks in psoriatic disease, which 
can be used to describe the disease pathology. The most striking feature of 
psoriasis is the marked increase in keratinocyte proliferation, which is accompanied 
by increased angiogenesis, and immune cell infiltrate.  
 
Differentiation of keratinocytes normally takes around 5 weeks, however in 
psoriatic tissues this is greatly accelerated, taking only 3-4 days. This leads to 
thickening of the skin (acanthosis) and incomplete terminal differentiation that 
normally occurs in granular keratinocytes, leading to squamous keratinocytes 
retaining their nuclei (parakeratosis). Extracellular lipids that are normally involved 
in cementing together the stratum corneum are underproduced, leading to the 
flaking scale seen in psoriatic skin (De Rosa & Mignogna 2007). 
 
Psoriatic lesions show marked vascular changes. Dermal papillary capillaries 
demonstrate morphological alterations before epidermal hyperplasia becomes 
evident (Kulka 1964). Capillaries are dilated, tortuous and demonstrate increased 
permeability, facilitating increased leukocyte migration to lesions (Heidenreich et 
al. 2009). The morphological vascular changes in psoriatic lesions are eloquently 
demonstrated in a clinical setting via eliciting Auspitz sign, which describes pinpoint 
bleeding when lesions are mechanically descaled. Papillary micro-vessels also 
demonstrate upregulation of inflammation associated adhesion molecules such as 
intracellular adhesion molecule (ICAM), vascular cell adhesion protein (VCAM) and 
E-Selectin, facilitating leukocyte adhesion to the endothelium (Springer 1994). Pro-
angiogenic mediators including vascular endothelial growth factor, hypoxia 
inducible factors, angiopoietin, as well as cytokines like TNFα, IL-8, and IL-17 are all 
upregulated in psoriasis (Heidenreich et al. 2009). 
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The neovascularization and hyperproliferation observed in psoriatic disease can be 
explained by the institution of an inflammatory cytokine network by resident 
epithelial, stromal, immune cells as well as infiltrating T lymphocytes and cells of 
the innate immune system. 
 
1.2.2 Role of Keratinocytes and Innate immunity 
 
Keratinocytes and the innate immune system provide a non-specific, rapid response 
to damage and infection, which is dysregulated in psoriasis. Besides forming the 
barrier of human skin, keratinocytes can be a source of antimicrobial peptides such 
as b-defensins, psoriasin (S100A7) and cathelicidin (LL-37). Generally, the 
antimicrobial peptides have chemotactic functions and can influence dendritic cells 
and T lymphocytes (Büchau & Gallo 2007). Besides producing antimicrobial 
peptides, keratinocytes can respond to interferon γ (IFN-γ), TNFα and IL-17, and are 
sources of IL-1 family cytokines, IL-8, C-X-C motif chemokine 10 (CXCL10) and C-C 
motif ligand 20 (CCL20). IL-8 production by keratinocytes has been shown to drive 
recruitment of neutrophils to the epidermis, where they form micro-abscesses. 
(Balato et al. 2012) 
 
Dendritic cells are antigen presenting cells and function as sentinels, bridging the 
gap between innate and adaptive immunity. When activated, dendritic cells migrate 
from the skin to draining lymph nodes, where they present antigens and activate a 
T cell response. Both dermal myeloid dendritic cells, and plasmacytoid dendritic 
cells (pDC) have repeatedly been shown to be significantly upregulated in psoriatic 
skin. Using a xenograft mouse model, a role for pDCs in the initiation of psoriasis 
was established, as although pDCs are usually tolerant to self RNA and DNA, LL-37 
has the potential to complex self or pathogen derived DNA and stimulate Toll-like 
Receptor 9 (TLR-9) on plasmacytoid dendritic cells. This results in host DNA 
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functioning as a proinflammatory stimulus in psoriasis (Kim et al. 2014). LL-37 can 
stimulate cytokines IL-1 family cytokines, including IL-36γ. Dendritic cells act the 
main source of IL-23 in psoriatic skin, which is a key cytokine in the IL-23/Th17 axis. 
It has been established that both TNFα and IL-36 stimulate IL-23 production by DCs, 
and that DCs are a critical source of TNFα and inducible Nitric Oxide Synthase 
(iNOS) in the psoriatic dermis. (Lowes et al. 2005) 
 
1.2.3 Role of T cells 
 
Although psoriasis involves both the innate and adaptive immune system, the 
importance of T cells was initially demonstrated by accident in when cyclosporine 
was successfully used in the treatment of psoriatic arthritis (Olivieri et al. 
1997).  More recently, T cell targeting biologic therapies, such as alefacept and 
efalizumab, have been very successful in the treatment of psoriatic disease 
(Rønholt & Iversen 2017). 
 
One of the best-studied pathways in psoriasis is the IL-23/Th17 axis. T helper 17 
(Th17) cells represent a specific subset of T-Lymphocytes characterised by their 
expression of IL-17, and are distinct from classical Type 1 T helper (Th1) 
lymphocytes (Steinman 2007). Like Th1 lymphocytes, Th17 cells play a significant 
role in the pathogenesis of psoriasis, amongst other chronic inflammatory diseases 
(Lowes et al. 2008;Neurath 2007). Predominantly, expansion and survival of this Th-
17 subset is driven by IL-23, a cytokine produced by myeloid cells, acting on 
memory T cells, since naive T cells lack an IL-23 receptor (Bettelli et al. 2007.) Other 
cytokines such as IL-9 have been shown to enhance Th17 associated inflammation 
in the context of psoriasis (T. P. Singh et al. 2013). Once activated Th17 cells 
produce IL-17, amongst other proinflammatory cytokines, inducing some of the 
hallmark changes associated with psoriasis such as keratinocyte hyperproliferation, 
and angiogenesis. The significance of this pathway is demonstrated by the success 
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of clinical trials of biologic therapies targeting the IL-23/IL-17 - axis (Fotiadou et al. 
2018). 
 
1.2.4 Fibroblasts in Immunity 
 
Fibroblasts are a heterogeneous population of stromal cells. Morphologically they 
are spindle shaped, with oval nuclei. There is no universal fibroblast marker and 
they lack markers associated with epithelial, vascular or leukocytic lineage. 
Traditionally recognised for their critical role in producing and remodelling 
extracellular matrix, it has also been demonstrated that they have the ability to 
maintain inflammatory cell infiltrates by responding to and producing relevant 
cytokines and chemokines (Jordana et al. 1994). Fibroblasts differ depending on 
their anatomical derivation, pathologies affecting tissues they are taken from, and 
even within tissues, and these differences persist even after in vitro culture (Chang 
et al. 2002).  
 
Fibroblasts produce the structural proteins, adhesive protein and ground substance 
that make up extracellular matrix, as well as being responsible for its maintenance 
and reabsorption. They play an active role in wound healing, angiogenesis, 
inflammation, fibrosis as well as supporting neoplastic progression. With regards to 
inflammation, fibroblasts are responsive to many inflammatory cytokines such as 
TNFα, IL-1β and IL-6, and in response can produce a variety of cytokines and 
chemokines (Van Linthout et al. 2014). The ability to respond to and produce 
growth factors and cytokines in a reciprocal fashion, allows fibroblasts to maintain 
homeostasis of local cells such as keratinocytes, endothelial cells or local immune 
cells. Fibroblasts support the generation of Th17 cells by enhancing release of IL-23 
by dendritic cells (Schirmer et al. 2010)  
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Fibroblasts demonstrate the ability to alter duration, intensity and cellular 
proportions of inflammatory responses, by providing a “stromal address code” 
(Parsonage et al. 2005), and there is evidence of crosstalk between fibroblasts and 
leukocytes. Fibroblasts are also critical in angiogenesis, where they produce 
vascular endothelial growth factor (VEGF), matrix proteins and cytokines which are 
indispensable for endothelial cell mediated lumen function (Newman et al. 2011).  
 
1.2.5 Fibroblasts in Psoriasis 
 
Because of their role in immune reactions, fibroblasts contribute to the 
inflammatory microenvironment in psoriasis. Fibroblasts respond to 
proinflammatory cytokines such as TNFα by induction of psoriasis associated 
messengers such as IL-6 and IL-8, and this induction is significantly higher in lesional 
fibroblasts compared to non-involved skin (Zalewska et al. 2006). However, it has 
been demonstrated that lesional fibroblasts alone cannot induce keratinocyte 
proliferation by supernatant or co-culture assay, nor do normal fibroblasts inhibit 
keratinocyte proliferation (Priestley & Lord 1990). It has been demonstrated that IL-
17A/TNF-α stimulation causes IL-8 release by fibroblasts (Yin et al. 2017). 
Modulation of neutrophil cytokine output has been demonstrated as a result of 
fibroblast-neutrophil interactions in the context of psoriasis (Glowacka et al. 2010). 
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1.3 MicroRNA 
 
Normal immune function can be regulated on a post-transcriptional basis by 
microRNA (miRNA), which are small, single-stranded non-coding RNAs around 22 
nucleotides long. They been demonstrated to regulate broad range of 
developmental and cellular processes, through binding to targets in the 3’ 
untranslated region (UTR) of target messenger RNA (mRNA) sequences, which 
ultimately represses protein expression through a variety of mechanisms. miRNA 
represent only around 3% of the human genome, however have the ability to 
regulate around 90% of genes (Pauley et al. 2009). The majority of miRNA are 
encoded by genes in the introns of protein coding genes, however they can also be 
found in either untranslated gene regions or intergenic regions. (Lee et al. 2004)  
 
In the context of immune function, miRNA genes have been shown to be controlled 
by activation of various mitogen Activated Protein Kinase (MAPK) pathways 
(Misawa et al. 2010), and NFκB (Gatto et al. 2008). Following their induction, 
microRNA have the potential to regulate multiple steps in immune responses, not 
limited to cytokine and chemokine expression, regulation of adhesion molecules, 
and cell polarisation (Zhou et al. 2011).  
 
The biogenesis of microRNA is a process which involves multiple processing steps 
both inside and outside the nucleus. A long primary miRNA (pri-miRNA) transcript is 
generated in the nucleus by RNA polymerase II, and has a hairpin structure, within 
which the miRNA resides. This pri-miRNA is processed by a complex called 
Microprocessor, consisting of a nuclear RNAse III Drosha, and its essential co-factor 
DiGeorge Syndrome Critical Region 8 (DGCR8), resulting in a miRNA precursor (pre-
miRNA) of ~70 nucleotides. Following nuclear processing, pre-miRNAs are exported 
into the cytoplasm by Exportin 5 (XPO5). In the cytoplasm the pre-miRNA is cleaved 
by an RNAse III Dicer which interacts with two cofactors, the HIV-1 TAR RNA Binding 
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Protein (TRBP) and protein activator of PKR (PACT), resulting in a small RNA duplex. 
An RNA-induced silencing complex is formed when the RNA duplex is loaded onto 
an Argonaut protein (AGO). One strand of the duplex (the passenger) is removed, 
leading to a mature RNA-Induced Silencing Complex (RISC) (Krol et al. 2010). 
 
RNA silencing can then occur via translational repression, mRNA deadenylation, or 
decay, facilitated by AGO recruitment of active factors. The miRNA functions as a 
guide, with a 6-8 nucleotide stretch, known as the seed region being critical in 
binding with target mRNA, and the degree of complementarity determining the 
mechanism of silencing (Kehl et al. 2017). miRNA demonstrate both redundancy 
and pleiotropy, meaning complex regulatory networks can form between miRNA 
and their target mRNAs.  
 
Since microRNA act to regulate normal immune function, alterations in their 
expression can influence disease pathologies. Several miRNAs have been identified 
as being dysregulated generally in inflammatory disease, with specific miRNA 
profiles exhibited in psoriatic inflammation (R. P. Singh et al. 2013; Joyce et al. 
2011).  Certain miRNAs can be used prognostically, and correlate with Psoriasis 
Severity Index (PASI) (Ichihara et al. 2012), and miRNA profiles alter following 
different systemic treatments (Hawkes et al. 2016).  
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1.4 IL-36 
 
Recently a pivotal cytokine for psoriasis has been identified in IL-36.  IL-36 cytokines 
are novel members of the IL-1 cytokine family, and include agonists IL-36α, IL-36β, 
and IL-36γ (previously identified as IL-1F6, IL-1F8, and IL-F9) as well as a natural 
antagonist IL-36Ra (previously known as IL-1F5) (Sims & Smith 2010). IL-36 
cytokines are much more tissue-specific than IL-1, generally its receptors are 
involved in the regulation of tissue-specific inflammation and expression is 
generally limited to tissues such as skin, lung, and gut (Ding et al. 2018). 
 
 
 
 
 
 
 
 
 
 
Figure 1. IL-36 Receptor Signalling 
The IL-36 receptor requires two components for signalling, IL-36R (IL-1Rrl2) and a co receptor, IL-1 
Accessory Protein (IL-1AcP) which is shared with the IL-1 Receptor. IL-1AcP has no capacity for 
signalling on its own. Following binding between an IL-36 cytokine and IL-36R, IL-1AcP is recruited, 
leading to interactions of the TIR domains of the two proteins, and subsequent activation of MAPK 
and NFκB pathways. (Towne et al. 2004) Downregulation occurs via IL-36RA which can successfully 
bind IL-36R, however does not result in recruitment of IL-1AcP, nor any downstream signalling 
(Gabay & Towne 2015). IL-36g is not released in an activated form and required processing by 
cathepsin S leading to a dramatic increase in its activity (Ainscough et al. 2017)  
Figure 1: IL-36 Receptor Signalling 
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1.4.2 IL-36 in psoriasis 
 
Much of the research surrounding IL-36 has taken place in the context of psoriatic 
disease, where it has been shown to be highly upregulated, and function as a 
biomarker. IL-36 has been shown to be upregulated in gene expression studies 
(Blumberg et al. 2007) as well as the functioning protein (D’Erme et al. 2015).  IL-36 
could be valuable in delineating between different clinically similar skin diseases 
such as atopic dermatitis and psoriasis. Strong expression of IL-36γ is seen in the 
upper epidermal layer of psoriatic skin, compared to other inflammatory skin 
diseases where it is only weakly expressed (D’Erme et al. 2015). Serum levels of IL-
36 are enhanced in psoriasis compared to other inflammatory skin conditions, and 
importantly correlate well with disease severity (as measured by PASI), not only in 
untreated individuals, but also in patients who underwent anti-TNF therapy where 
IL-36 in serum decreased with symptoms of disease (D’Erme et al. 2015). 
 
IL-36 is thought to be mainly  produced by  keratinocytes  and other  epithelial cells 
in response to inflammatory  mediators  such  as  TNF-a and  IL-1 (Carrier et al. 
2011). IL-36 has effects on a range of cell types including epithelial cells, fibroblasts 
and immune cells. IL-36 contributes to psoriatic inflammation via its central position 
in the interplay between immune cells and keratinocytes. Over-expression of IL-36 
in mouse skin results in a phenotype that is similar to psoriasis, with regards to 
acanthosis, hyperkeratosis and inflammatory infiltrate. Genes associated with 
psoriasis such as IL-17, IL-22, IL-23, antimicrobial peptides and S100 proteins are 
also upregulated (Towne & Sims 2012).  
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There is evidence of multiple mechanistic links between IL-36 and the IL-23/17 axes. 
IL-17 can induce IL-36 from human keratinocytes, and the degree of this induction 
is significantly stronger in non-lesional skin from psoriasis patients, than it is from 
unaffected individuals (Muhr et al. 2011). IL-36γ induces its own expression as well 
as that of TNFα, IL-6 and IL-8 in keratinocytes (Carrier et al. 2011). Stimulation with 
IL-36 leads to the production of IL-23 by macrophages, and this induction is 
enhanced in macrophages of psoriasis patients (Bridgewood et al. 2018). IL-36 
augments IL-17’s role in the production of antimicrobial peptide production (Carrier 
et al. 2011). This describes a feedback loop for IL-36, in which it is not only 
regulated by Th-17 cytokines, but also enhances their activity.  
 
Interestingly, in certain individuals affected by generalised pustular psoriasis, a loss 
of function mutations of IL-36RA has been identified (Marrakchi et al. 2011). Due to 
loss of control of IL-36 antagonist activity by IL-36RA, IL-36 stimulation of cells from 
patients with mutated IL-36RA (keratinocytes or peripheral blood mononuclear 
cells) induced cytokines (IL-1α, IL-6, IL-8, TNFα) more strongly than it did in cells 
from control individuals. (Onoufriadis et al. 2011) (Marrakchi et al. 2011)  
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Figure 2. Role of IL-36 in Psoriasis Pathology 
IL-36 is released by epithelial cells, following inflammatory stimulation. IL-36 can act on 
keratinocytes in both autocrine and paracrine fashion, leading to increased proliferation, 
as well as inducing itself and other proinflammatory cytokines.  IL-36 has actions on 
fibroblasts and local immune cells such as dendritic cells, through which a Th1/17 
response is driven. This T cell driven response creates further inflammatory stimulus for 
keratinocytes and contributes to the establishment of a proinflammatory cytokine and 
chemokine network.  
Figure 2: Role of IL-36 in Psoriasis Pathology 
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1.5.1 mTOR  
 
Mechanistic Target Of Rapamycin (mTOR) is a serine/threonine kinase that is a 
central regulator of metabolic control, and is highly conserved from yeast to 
humans. mTOR is sensitive to a wide range of extracellular signals, such as growth 
factors, hormones, cytokines as well as ligation of TLRs and T-cell Receptors (TCR). 
mTOR has also developed to respond to intracellular cues, and is responsive to 
nutrient availability (including amino acids and glucose), and cellular energy change 
(AMP: ATP ratio). In response to signals mTOR regulates cell growth and 
proliferation via a variety of targets (Laplante & Sabatini 2012). 
 
1.5.2 mTOR complexes 
 
mTOR exists in two discrete, interacting complexes that differ both structurally and 
functionally. mTORC1 is the better characterised of the mTOR complexes. It 
contains mTOR; regulatory protein associated with mTOR (Raptor), and mammalian 
lethal with Sec13 protein 8 (mLST8, aka GßL) (Kim et al. 2003). Furthermore, 
mTORC1 is also comprised of the two inhibitory subunits Proline-Rich AKT substrate 
of 40 kDa (PRAS40) and DEP domain containing mTOR interacting protein (Deptor) 
(Sancak et al. 2007).  
 
mTORC2 shares mTOR and mLST8 (Jacinto et al. 2004), however Rapamycin 
insensitive companion of mTOR (Rictor) replaces raptor (Sarbassov et al. 2004). 
mTORC2 also contains the regulatory proteins mSin1 and Protor1/2 (Pearce et al. 
2011; Frias et al. 2006).  
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1.5.3 Upstream of mTOR 
 
A key upstream regulator of mTOR is the heterodimeric Tuberous Sclerosis Complex 
(TSC), which is comprised of TSC 1 (hamartin) and TSC 2 (tuberin). TSC is named 
after a multi-systemic disease, that is due to mutations in the genes encoding for 
either of the components of the heterodimer. TSC is characterised by malformation 
and multiple benign tumours, illustrating both the proliferative role of mTOR and 
TSC1/2’s place as a key negative regulator (Lam et al. 2017).  
 
TSC1/2 exerts its effects on mTORC1 by acting as a GTP-activating protein for Ras 
Homolog Enriched in the Brain (Rheb). Rheb interacts with mTORC1 directly to 
stimulate activity, and is rendered inactive when guanosine diphosphate (GDP) 
bound (Inoki et al. 2003). Many signals converge on TSC1/2, and canonically it is 
downstream of growth factors, via the phosphoinositide 3-kinase (PI3K) and Ras 
pathways. Kinases such as protein kinase B (AKT), extracellular signal related 
kinases 1/2 (ERK1/2), and ribosomal protein S6 kinase 1 (S6K1) phosphorylate 
TSC1/2, removing its opposition to mTORC1 activity (Laplante & Sabatini 2012). 
 
Much like growth factors, proinflammatory cytokines such as TNFα have been 
demonstrated to relieve TSC1/2 control of mTORC1 via IkB Kinase beta (Lee et al. 
2007). Signals can also converge on mTOR via TSC independent mechanisms, for 
instance AKT, which can directly phosphorylate PRAS40, an mTORC1 inhibitor 
(Sancak et al. 2007). 
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1.5.4 Downstream of mTOR 
 
The best characterised function of mTORC1 is increased protein output, via targets 
such as S6K1 and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). As the 
rate limiting step in protein synthesis is translation initiation, it makes sense that 
4E-BP1 is an output of mTOR. Following phosphorylation, 4E-BP1 cannot bind to the 
cap-binding protein eukaryotic translation initiation factor 4 (eIF4E), facilitating the 
formation of the eIF4F complex, promoting cap-dependent translation (Ma & Blenis 
2009).  
 
S6K1 positively controls protein synthesis through a variety of mechanisms 
including enhancing translation initiation and increasing ribosome biogenesis 
(Sabatini 2017). mTORC1 also has a role in positively regulating metabolism and 
adenosine triphosphate (ATP) production, and in the presence of favourable growth 
signals mTORC1 acts as a strong negative regulator of autophagy, through 
phosphorylation and inactivation of Unc-51 Like Autophagy Activating Kinase 1 
(ULK1) (Nazio et al. 2013). 
 
Like mTORC1, mTORC2 is sensitive to growth factors in a PI3K dependent fashion, 
however amino acids do not seem to influence its activation (Laplante & Sabatini 
2012). By direct phosphorylation of AKT on Ser473, mTORC2 enhances some of its 
functions, such as shifting towards glycolytic metabolism, and a Forkhead Box 
protein O1 (FOXO1) mediated transition towards growth (Sarbassov et al. 2005). 
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1.5.5 Regulatory loops affecting mTOR 
 
Due to the broad activity of mTOR and its wide range of inputs, it is understandable 
that it is a tightly regulated system involving multiple feedback loops. In order to 
avoid unbridled mTOR activation, PI3K is inhibited by mTORC1 at multiple levels. 
S6K1 inhibits Insulin Receptor Substrate 1 (IRS1) through phosphorylation and 
relocalisation, resulting in impaired signalling (Takano et al. 2001). Via an analogous 
mechanism, S6K1 also inhibits PI3K activation from Platelet-Derived Growth Factor 
Receptors (PDGFR) (Zhang et al. 2007). It has been demonstrated that S6K1 also 
inhibits ERK/MAPKs (Carracedo et al. 2008).  
 
There are also feedback loops between the mTOR complexes. Phosphorylation of 
AKT on Ser473 by mTORC2 is necessary for its maximum activation when 
phosphorylated by Phosphoinositide-Dependent Kinase 1 (PDK1) on Thr308. This 
means that mTOR functions both up and downstream of AKT (Sarbassov et al. 
2005). Independent of its action on mTORC1, TSC seems to be necessary for 
mTORC2 activity (Huang et al. 2008). S6K1 leads to phosphorylation of Rictor, which 
does not impact most mTORC2 targets, but does reduce phosphorylation of AKT 
Ser473 (Dibble et al. 2009).  
 
Inhibition of mTORC1 via rapamycin results in upregulation of mTORC2 activity, as 
measured by phosphorylation of AKT on Ser473 due to the previously mentioned 
feedback pathways. These overlapping mechanisms have been cited as mechanisms 
for the failure of rapalogs in a variety of disease states, including both inflammatory 
disease and cancer (Faes et al. 2017; Raychaudhuri & Raychaudhuri 2014).   
 
 
 
27 
 
1.5.6 mTOR in immune function 
 
Appropriate degrees of mTOR activation have been demonstrated to be essential 
for shaping immune responses from a wide range of cells in both the innate and 
adaptive immune systems. Particular effects directly attributable to mTOR include 
regulating metabolism, cytokine response, antigen presentation, the polarisation of 
both macrophages and T cells, and the migratory potential of immune cells 
(Weichhart et al. 2015; Powell et al. 2012). 
 
T cells appear to be extremely sensitive to mTOR inhibition, as demonstrated by the 
fact that rapamycin is highly effective in inhibiting antigen-induced T cell 
proliferation (Sehgal & Bansbach 1993). This has led to relatively widespread use 
clinically where it is effective in preventing organ rejection (Calne et al. 1989). 
Rapamycin has also proven to be effective in treatment of immune mediated 
disorders such as Systematic Lupus Erythematosus (SLE) (Fernandez et al. 2006). 
With respect to the polarisation of T cells, mTORC1 seems to be essential for the 
differentiation of Th1 and Th17 cells, and the development of Th2 cells depends on 
mTORC2 (Delgoffe et al. 2011).  
 
In cells of the innate immune system, however, it would appear that mTOR has 
different roles depending on cell type, with mTORC1 inhibition resulting in 
increased inflammatory output in Peripheral Blood Mononuclear Cells (PBMCs) as 
measured by their capacity to produce proinflammatory cytokines (Weichhart et al. 
2008; Byles et al. 2013). Whereas in neutrophils, mTOR inhibition results in 
decreased migration and activity (Gomez-Cambronero 2003). Modulation of mTOR 
activity can affect the way non-immune cells respond to inflammatory stimuli. It has 
been demonstrated in Fibroblast-Like-Synoviocytes (FLS) that, in a nutrient rich 
environment, mTOR signalling significantly decreases NFκB gene expression 
(Karonitsch et al. 2018).  
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1.5.6 mTOR in Psoriasis 
 
Enhanced activation of mTOR and its downstream effectors has been observed in 
lesional psoriatic skin, and the degree of its activation has been linked to disease 
severity  (Buerger et al. 2013;Raychaudhuri & Raychaudhuri 2014). It has been 
suggested that the inflammatory environment in psoriasis activates mTOR 
inappropriately, and that mTOR regulates both the proliferation of keratinocytes 
and induction of relevant cytokines (Raychaudhuri and Raychaudhuri 2014). 
Deregulation mTORC1 signalling is not limited to skin and was identified in PBMCs 
of psoriasis patients (Huang et al. 2014) 
 
Based on the activation of mTOR in psoriatic skin, and the use of mTOR inhibition in 
successful immunosuppression regimes, mTOR inhibition seemed like a promising 
therapy for relieving psoriasis symptoms. However, although mTOR inhibition 
seems to be able to ameliorate imiquimod induced psoriasis in mice (Bürger et al. 
2017), trials of topical sirolimus in a double blind study,  revealed only a mild anti-
psoriatic effect of mTOR inhibition in affected humans. Although there was a 
reduction in clinical score, as well as a histological reduction in CD4+ and 
proliferating cells, the effects were only modest, and there was no measurable 
alteration in plaque thickness or erythema (Ormerod et al. 2005).   
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1.5.7 mTOR in Fibroblasts 
 
The effects of mTOR inhibition on fibroblasts have also been studied to some 
degree. It has been shown in dermal fibroblasts that mTOR enhances collagen 
production, and rapamycin treatment leads to some improvements in systemic 
sclerosis, a fibroblast mediated disease (Tamaki et al. 2014). The effects of mTOR 
inhibition in fibroblasts also extend to cytokine signalling. In human orbital 
fibroblasts, rapamycin treatment has been demonstrated to enhance TNFα 
production of proinflammatory cytokines (Lee et al. 2013).  
 
Although the effect of mTOR inhibition has been well studied in a variety of 
immune cell types, how it affects stromal cell contribution to the psoriatic 
environment remains to be elucidated.  
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1.6 Project aims 
 
The aims of this project were to: 
1) determine the effect of IL-36γ on psoriasis-associated proinflammatory 
mediators and adhesion molecules in HFFs;  
2) explore the effect of IL-36γ on signal transduction with a focus on the mTOR 
pathway  
3) test whether mTOR modulation alters IL-36γ induced cytokine signalling in 
fibroblasts. 
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2 Materials and methods 
2.1 Cell culture 
 
Human foreskin fibroblasts (HFFs) were obtained from frozen stocks in Lagos Lab, 
and were initially purchased from ATCC (PCS-201-012). HFFs were grown in 
Dulbecos Modified Eagle Medium (DMEM) (Gibco), supplemented with 10% foetal 
calf serum (FCS) (Hyclone), 1% L-Glutamine (Gibco), and 1% penicillin/streptomycin 
(Gibco) in 10cm dishes (BD Falcon). All experiments were seeded at 5 x 104 cells per 
well of 6 well plates (BD Falcon) and grown for 16h-24h prior to any treatment or 
starvation. Where indicated, serum starvation took place in DMEM for 16 hours. 
 
2.2 siRNA knockdown 
 
A transfection mix comprised of Opti-MEM (Invitrogen), TransIT-siQuest (Mirus), 
and siTSC (Dharmacon) or siNTC (Dharmacon) according to the manufacturer’s 
recommended instructions. SiRNA were used at a final concentration of 50nM, and 
volume of 800μl. After 6 hours, transfection mix was supplemented by 10% FCS 
DMEM. Media/transfection mix was removed and washed with phosphate buffered 
saline (PBS) following 16 hours, and fresh media was added. Assays were 
performed 24 hours later.  
 
2.3 RNA Extraction 
 
Prior to RNA extraction, work surfaces and pipettes were treated with RNAase ZAP 
(ThermoFisher). For adherent cells, lysis was performed directly on 6 well plates 
(initially seeded with at 5 x 104 cells per well) using 700μl of Qiazol (Qiagen). For 
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non-adherent cells, lysis was performed with 700μl of Qiazol (Qiagen) on a 
centrifuged pellet of 1 x 105 cells. 
Lysates were frozen at -80˚C until RNA extraction. From this point RNase-free tubes 
(Appleton) were used for all elements of RNA work. RNA extraction was performed 
using mMiRNeasy mini kit (Qiagen) according to the manufacturer’s instructions. 
RNA was eluted using 30μl of RNAse free H2O, and immediately analysed using a 
Nanodrop (2000 ThermoFisher) with 1μl of sample. Absorbance at 260/280 was 
used to determine RNA purity, and A260/230 to assess for contaminants such as 
remaining phenol.   
 
2.4cDNA synthesis 
 
cDNA synthesis for mRNA was performed using random hexamers. At least 1μl of 
RNA sample was incubated with 1μl random Hexamers (50ng/μl), 1μl of dNTP mix 
(10μM) and made up to 12.5μl with Nuclease free H2O. Samples were then 
incubated at 65˚C for 5 mins, and kept on ice, until the addition of 4μl of First 
strand buffer (Invitrogen), 2μl of 0.1M DTT (Invitrogen), 1μl of RNaseOUT 
(Invitrogen) and 1μl of superscript III (Invitrogen). Sample and reverse transcription 
mix were incubated at 25˚C for 10 mins, 50˚C for 50 minutes, and 5 minutes at 85˚C 
to terminate reaction. cDNA was stored at -20˚C or used for qPCR immediately. For 
miRNA, prior to reverse transcription, RNA was diluted to give 3ng μl-1 . miRNA 
cDNA synthesis using the TaqMan® miRNA reverse transcription Kit (Applied 
Biosystems), following the manufacturer’s instructions. Samples were stored at -
20˚C or used immediately for q-RT PCR.  
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2.5 Quantitative Reverse Transcription PCR (qRT-PCR) 
 
Primers used for target sequences using either SYBR Green (Applied Biosystems) or 
TaqMan primers are detailed in Table 1. Each reaction contains 1μl of cDNA, 10μl of 
SYBR Green mix (Applied Biosystems), 0.6μl of forward primer, 0.6μl of reverse 
primer, and 7.8μl of nuclease-free water. MicroAmp Fast Optical 96 well reaction 
plates (Applied Biosystems) were sealed using MicroAmp Optical adhesive film 
(Applied Biosystems) and centrifuged at 1200g for 90 seconds. StepOnePlus Real 
Time PCR systems (Applied Biosystems) were used for 40 cycles, and thresholds 
determined using StepOne software (Applied Biosystems). Generation of a single 
amplicon was confirmed through melt curve analysis, also using StepOne software 
(Applied Biosystems).  
GAPDH and U6 were used as loading controls for mRNA and miRNA respectively, 
and where appropriate (i.e. target was readily detectable) the ΔΔCT method was 
used to determine the relative expression of targets. Table 1: Primer sequences 
Table 1. Sequences of primers for target genes 
Target Primer Sequence 
GAPDH (F) 5′-GGAGTCAACGGATTTGGTCGTA-3′ 
GAPDH (R) 5′-GGCAACAATATCCACTTTACCAGA-3′ 
IL-1RAcp (F) 5′-GACCCTCCGTGGAGTTTTGGAGAA-3′ 
IL-1RAcp (R) 5′-TAGAACAACCAGGAGGCGTC -3′ 
IL-36 Receptor (F) 5′-GCTGGAGTGTCCACAGCATA-3′ 
IL-36Receptor (R) 5′-GCGATAAGCCCTCCTATCAA-3′ 
IL-1β (F) 5′-AGGATGACTTGTTCTTTGAAGCTGA -3’ 
IL-1β (R) 5′-TGCCTGAAGCCCTTGCTG -3′ 
IL-8 (F) 5′-ATGACTTCCAAGCTGGCCGTGGCT -3′ 
IL-8 (R) 5′-TCTCAGCCCTCTTCAAAAACTTCTC-3′ 
VCAM (F) 5′-CGTCTTGGTCAGCCCTTCCT -3′ 
VCAM (R) 5′-ACATTCATATACTCCCGCATCCTTC -3′ 
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ICAM (F) 5′-AGGCCACCCCAGAGGACAAC -3′ 
ICAM (R) 5′-CCCATTATGACTGCGGCTGCTA -3′ 
 
2.6 Protein Extraction and Quantification  
 
Protein extraction was performed using radioimmunoprecipitation assay buffer 
RIPA buffer (see appendix), supplemented using Protease Inhibitor Cocktail 
(containing AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, and Pepstatin A), 
Phosphatase Inhibitor Cocktail 2 (containing sodium orthovanadate, sodium 
molybdate, sodium tartrate, and Imidazole) and 3 (containing cantharidin, 
Bromolevamisole oxalate and Calyculin A) all from Sigma. Following removal of 
supernatant, plates were washed with cold PBS, which was carefully removed from 
the tilted plate. Between 30μl and 45μl of RIPA was then used, depending on 
confluence, due to increased viscosity of lysate with higher cell numbers. RIPA was 
then spread and lysate collected using a cell scraper, before being pipetted into 
Eppendorfs and placed on ice. Lysates were spun at 10,000g for 15mins at 4˚C and 
the supernatant removed and stored at -20˚C. 
 
Quantification of proteins was performed using Pierce BCA Protein Assay Kit 
(Thermofisher Scientific). 1000μg ml-1 Albumin provided with the Kit was serially 
diluted 6 times and used to generate a standard curve. Samples were diluted 1:5, 
with 5μl added to 95μ BCA reagent mix. Samples were prepared in duplicate and 
incubated in 96 well tissue culture plates at 37˚C for 30 mins. Absorbance was 
measured at 562nm and concentrations calculated relative to a standard curve.  
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2.7 Western Blotting 
 
Protein lysates were prepared to give 10μg of protein per sample where possible, 
however in circumstances where limited protein was available in some samples this 
was scaled to be as low as 6μg per well. Lysates were prepared using 5μl of 4x SDS 
reducing sample buffer (see appendix). 
Protein denaturation was performed at 95˚C for 10mins, then samples were placed 
on ice prior to loading. 18μl of denatured sample, and 8μl of Page Ruler Plus 
(Thermofisher Scientific) were loaded into appropriate lanes, and 4.5μl of 4x SDS 
sample loading buffer into remaining empty lanes. Protein separation was 
performed on a 1.5mm thick 12% polyacrylamide gel (recipe below) in SDS-Page 
buffer (National Diagnostics) using the mini-PROTEAN tetra system (BioRad) for 
90mins at 120V.  
Transfer was performed at 0.2A, 25V for 65 minutes using semi-dry transfer 
machine (BioRad) and Transfer Buffer (National Diagnostics) with 10% methanol. 
Proteins were transferred to a polyvinyl fluoride (PVDF) membrane (Immobilon), 
which was activated for 1 minute in methanol and 1 minute in ddH2O, before being 
stored in transfer buffer. Following transfer, membranes were blocked in 2% (w/v) 
BSA-TBS/T for 1 hour at room temperature on rollers in a 50ml Falcon Tube. 
After blocking, membranes were incubated with 5-10ml of primary antibody (Table 
2), at 4˚C overnight, again in a 50ml Falcon Tube on a roller. Primary antibodies 
were then removed, and membranes washed 3 times for 5 mins in TBS/T on a 
rocking platform. Membranes then underwent a 1-hour room temperature 
incubation in an appropriate horseradish peroxidase (HRP) conjugated secondary 
antibody in another 50ml Falcon tube on a roller.  
Membranes then underwent another 3 washes, before visualisation which was 
performed using Enhanced Chemiluminescent (ECL) western blotting reagent (GE 
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Healthcare). Signal was detected using either Hyperfilm ECL (GE Healthcare) using 
dark room facilities or using a Chemidot™ (BioRad). 
Following detection, membranes were washed and re-probed for new targets and, 
when necessary, blots were stripped for 15 minutes in Bright Clear Stripping Buffer 
(Thermo) at room temperature, on a shaking platform, before being blocked as 
above.  
Films were scanned at 600 DPI, and chemiluminescence images were saved as TIFs, 
with the signal from each band being quantified by densitometric analysis using 
ImageJ. Band signal was normalised against β actin, for each lane as a loading 
control.  
 
Table 2. Antibodies used for Western Blot 
Antibody Manufacturer Source Dilution 
pAKTthr308 (C31E5) CST Rabbit 1:1000 
4% BSA 
pAKTser473 (D9E) CST Rabbit 1:1000 
4% BSA 
AKT (C67E7) CST Rabbit 1:1000 
4% BSA 
P-S6 (#2215) CST Rabbit 1:1000 
4% BSA 
S6 (5G10) CST Rabbit 1:1000 
4% BSA 
β-actin (ab6276) Abcam Mouse 1:5000 
5% Milk 
Polyclonal Goat Anti-Mouse Immunoglobulins/HRP DAKO Goat 1:5000, 
5% milk 
Polyclonal Goat Anti-Rabbit Immunoglobulins/HRP DAKO Goat 1:5000, 
5% milk 
Table 2: Antibodies used for Western Blot 
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2.8 Enzyme-linked Immunosorbent Assay 
 
HFFs were seeded at 5 x 104 cells per well, in 6 well plates, and 24 hours later, 
underwent relevant pre-treatments, transfection or stimulations. Wells were 
washed in PBS before having 650μl of media and stimulant added. Media was 
collected and frozen at -80˚C until use. Media was spun for 5 mins at 300g 4˚c and 
supernatant collected into fresh Eppendorf tubes. Nunc plates (Thermo Scientific) 
were incubated overnight, 4˚C with 50μl of 1:200 capture antibody in commercially 
obtained carbonate coating buffer pH 9.5 (BioLegend). 
Plates were then washed four times in TBS/T (see Appendix) before blocking for 1 
hour in 5% FCS TBS/T, on a gently rocking platform at room temperature. After 
washing another four times, samples and standards were added and incubated for 
2 hours at room temp. Standards were prepared in 5% FCS TBS/T using serial 
dilution. Where appropriate, based on preliminary experiments, samples were 
diluted 1:5, 1:10 or 1:20 in 5% FCS TBS/T. 
Following washing, plates were incubated with 50μl of detection antibody solution 
(1:200), in 5% FCS for 1 hour. After washing a further four times, plates were 
incubated with 50μl of avidin-HRP for 30 minutes at room temperature. After a final 
wash involving repeated 30 second soaking steps, 100μl of TMB solution (1:1 A+B 
BioLegend) was added until an appropriate colour changes evolved; approximately 
25 minutes. To stop the reaction, 100μl of 1M sulphuric acid was added. Plates 
were read at 450nm and 570nm, using Molecular Devices Spectromax 
Monochromatic Reader, then analysis was performed in SoftMax Pro. 
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2.9 Statistics 
 
Results are presented as mean ± standard error of the mean (SEM). All statistical 
tests and graphs were generated in GraphPad Prism 6 (GraphPad Software). One-
way ANOVA and paired T tests were used where appropriate and is indicated in 
figure legends. 
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3 Results 
3.1 HFFs express IL-36R and respond to IL-36γ  
 
Since both IL-36R and IL-1AcP are required for signalling due to IL-36γ, and IL-36R is 
expressed in a cell type restricted fashion, confirmation that primary human 
foreskin fibroblasts express IL-36R and its co-receptor IL-1AcP was necessary. HFFs 
represent a ready source of dermal fibroblasts that are taken from healthy donors 
without local pathology. They are easily obtainable, well categorised, and 
commonly used as model fibroblasts in the study of skin pathologies and psoriasis 
(Yin et al. 2017).   
Confirmation of receptor components in HFFs was performed using qRT-PCR, both 
of which were demonstrated to be present through comparison between the raw 
Ct values obtained from HFF cDNA and the NTC (p<0.0001). IL-36R mRNA was not 
readily detectable in JURKATs, an immortalised T lymphoma cell line (Figure 3).  
In HFFs, FCS was shown to result in a statistically insignificant trend towards 
upregulation of both the receptor and IL-1AcP mRNA compared to unstimulated 
samples (Figure 4). IL-8 was measured to assess for a functional response to IL-36γ, 
and stimulation caused an upregulation of IL-8 mRNA (p=0.0016) (Figure 5A). This 
effect was also observed by ELISA (p=0.0015) (Figure 5B). It is noteworthy that the 
degree of this induction is more pronounced on a protein level than mRNA. 
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Figure 3. qRT-PCR Analysis of IL-36R and IL-1AcP in HFFs and JURKATs. Untreated HFFs and JURKATs 
were analysed for (A) IL-36R and (B) IL-1AcP. In samples where target was undetectable, CT was set 
to 40 cycles. For HFFs and JURKATs, n ≥ 5. (A) IL-36R was detectable in HFFs, however there was no 
significant difference between JURKAT and NTC. (B) IL-1AcP was readily detected in both HFFs and 
JURKATs. Significance was determined via one-way ANOVA. 
Figure 3: qRT-PCR Analysis of IL-36R and IL-1AcP in HFFs and JURKATs. 
 
 
 
Figure 4. FCS upregulates IL-36R and IL-1AcP mRNA in HFFs. HFFs were serum starved for 24 hours, 
before 6 hours stimulation with 10% FCS and 100ng/ml IL-36. Sample mRNA is normalised to GAPDH. 
qRT-PCR analysis demonstrates that FCS upregulates both (A) IL-36R and (B) IL-1AcP, however IL-36 
stimulation does not alter expression of the receptor. n = 4. Significance was determined via one-way 
ANOVA. 
Figure 4: FCS upregulates IL-36R and IL-1AcP mRNA in HFFs. 
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Figure 5. IL-36 Induced IL-8 in HFFs. HFFs were treated with 100ng/ml IL-36γ and analysed after (A) 6 
hours and (B) 24 hours by qRT-PCR and ELISA respectively. Sample mRNA is normalised to GAPDH. 
(A) n = 6. (B) n = 3. IL-8 upregulation was on both a mRNA and protein level. Significance was 
determined via paired T test.  
Figure 5: IL-36 Induced IL-8 in HFFs. 
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3.2 IL-36γ induces proinflammatory cytokines and 
adhesion molecules 
To investigate the proinflammatory effects of IL-36 on HFFs, archetypal 
proinflammatory cytokine IL-1β, chemokine IL-8, and adhesion molecules ICAM and 
VCAM were measured. Serum starvation was performed since there are many 
unidentified proteins in FCS that may interfere with IL-36. Additionally, FCS induces 
its own changes in cells due to its high concentration of growth factors, proteins 
and cytokines, so subtle effects may not be observable behind its stimulation. 
Treatment with FCS does, however, give an indication of the general effect of 
growth factors on induction of cytokines and adhesion molecules. 
In serum-starved conditions, there was a trend towards upregulation of IL-1b and 
IL-8 mRNA, however this was not statistically significant for either (Figure 6 A+B). 
When treated with FCS and IL-36, IL-1 induction was observed (p=0.0038) however 
the same effect was not statistically significant for IL-8 mRNA (Figure 6 A+B). 
To determine protein production of chemokines, ELISA for IL-8 was performed. Any 
induction of IL-8 by IL-36 in serum-starved conditions was not statistically 
significant, however with FCS, IL-36 does induce IL-8 (p=0.0004) (Figure 7). 
With regards to adhesion molecules, no statistically significant effects were 
apparent. However there was a trend towards upregulation of ICAM mRNA when 
treated with FCS (p=0.0604)(Figure 6C). 
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Figure 6. FCS enhances induction of proinflammatory molecules by IL-36. HFFs were serum starved 
overnight, then treated with either 10% FCS or 100ng/ml IL-36γ. Sample mRNA is normalised to 
GAPDH.  qRT-PCR was performed for (A) IL-1, (B) IL-8), (C) ICAM and (D) VCAM at 6 hours, and (E) 
ELISA for IL-8 was performed at 24hours. n ≥ 4. Targets were normalised to unstimulated samples. 
Significance was determined via one-way ANOVA. 
Figure 6: FCS enhances induction of proinflammatory molecules by IL-36. 
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Figure 7. FCS increases IL-8 induction by IL-36. HFFs were serum starved overnight, then treated 
with either 10% FCS or 100ng/ml IL-36γ. ELISA for IL-8 was performed at 24hours. n = 4. 
Significance was determined via one-way ANOVA. 
Figure 7: FCS increases IL-8 induction by IL-36 
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3.3 IL-36γ upregulates miR-21  
 
To determine if microRNA are induced because of IL-36 stimulation in HFFs, we 
probed for five microRNA targets through qRT-PCR. MicroRNA to be examined were 
selected for being associated with both mTOR and psoriasis, with evidence 
suggesting their expression is altered in lesional tissues. miR-21 is a well-studied 
oncoMiR, elevated in psoriatic skin, and its expression has a strong correlation with 
TNFa mRNA (Guinea-Viniegra et al. 2014). It is associated with altered cytokine 
expression through STAT3 activation (Guinea-Viniegra et al. 2014) and matrix 
metalloproteinase production (Gabriely et al. 2008). miR-146a is a negative 
regulator of the innate immune response, via direct targeting of tumour necrosis 
factor receptor (TNFR)-associated factor 6 (TRAF6) and interleukin-1 receptor-
associated kinase 1 (IRAK1), both of which are important components in signal 
transduction for proinflammatory cytokines (O’Connell et al. 2012). It is has been 
found to be highly upregulated in psoriatic skin in a number of studies looking at 
different compartments and infiltrating immune cells (Løvendorf et al. 2015;Xia et 
al. 2012; Sonkoly et al. 2007). miR-155 is found to be elevated in psoriatic skin in 
some of the same studies (Løvendorf et al. 2015;Ichihara et al. 2011). miR-210 
upregulated in psoriasis(Lerman et al. 2011) Like miR-21, miR-221 is associated with 
the production of matrix metalloproteinases albeit in a negative fashion (Zibert et 
al. 2010). 
 
We identified that miR-21 is upregulated by IL-36γ stimulation in HFFs at 6 hours 
(p=0.0420) and there is possibly a non-significant trend towards upregulation miR-
221 (and p=0.1757) (Figure 8A + E). There does not appear to be any consistent 
modulation of miR-146a, miR-155 or miR-210 (Figure 8B-D). 
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Figure 8. IL-36 upregulates miR-21  HFFs were treated with 100ng/ml IL-36γ and analysed after 6 
hours by qRT-PCR for miR-21 (A), miR-146a (B), miR-155 (C), miR-210 (D) and miR-221. Sample 
miRNA is normalised to U6. Significance was determined via paired T test.  
Figure 8: IL-36 upregulates miR-21 
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3.4 IL-36γ induces IL-8 via NFκB 
 
To investigate IL-36 induced signal transduction, a pharmaceutical inhibitor of NFkB, 
BAY 11-7082, was utilised. In an unstimulated state, NFκB is maintained in an 
inactive form in the cytosol by association with regulatory proteins, termed 
inhibitors of κB (IκB). In response to inflammatory cytokines or cellular stresses, IκB 
is phosphorylated by IκB Kinase (IKK), which, together with the ubiquitination and 
proteolytic degradation of IκB, leads to the activation and nuclear translocation of 
NFκB. BAY 11-7082 exerts its effects by inhibiting the activity of IKK, thereby 
maintaining NFκB in its inactive complex with IκB (Pierce et al. 1997). 
BAY-11 treatment initially results in a reduction of basal IL-8 mRNA (p<0.0001) 
(Figure 9A), and although protein measured by ELISA does demonstrate a 
downregulation, the effect is not significant (p=0.0705) (see Figure 9B). BAY-11 also 
inhibited IL-36γ induced IL-8 mRNA (p<0.0001) (Figure 9A) and protein (<0.0001) 
(Figure 9B), indicating the cytokine inducing effects of IL-36γ are NFkB dependent.  
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Figure 9. NFκB inhibition eliminates basal and IL-36 induced IL-8 expression. HFFs 
were pre-treated with 10uM BAY 11-7082 for 1 hour, prior to stimulation with 
100ng/ml IL-36γ. Reduction in both basal and IL-36 induced IL-8 expression was 
observed by both (A) qRT-PCR and (B) ELISA. n=3. Sample mRNA is normalised to 
GAPDH. Significance was determined via one-way ANOVA. 
Figure 9: NFκB inhibition eliminates basal and IL-36 induced IL-8 expression. 
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3.5 IL-36γ modulates AKT and mTOR activity 
 
The key serine/threonine kinase AKT is activated following two phosphorylation 
events. AKT is phosphorylated on thr308 by PDK1 and on ser473 by mTORC2 
(Laplante and Sabatini 2012). Expectedly, no phosphorylation of AKT was 
observable in serum starved conditions, this was regardless of the administration of 
IL-36γ (Figure 10). FCS caused a significant upregulation of pAKTthr308 (p<0.0001), 
there was also an upregulation when treated with FCS alongside IL-36 (p=0.0026), 
however to a lesser degree than FCS alone (p=0.0007) (see Figure 11C). Similarly, 
unobservable while starved, pAKTser473 was strongly induced by FCS (p=0.0285). 
Again, this was ameliorated by concurrent IL-36γ treatment (p=0.2905) (Figure 
11D). This indicates that IL-36 does not activate AKT, and may have a role in its 
inhibition.  
 
pS6 is commonly used as a read out of mTOR signalling (Andreoli et al. 2015). In 
serum-starved cells pS6 signalling is only observable 30 minutes following DMEM 
replenishment (Figure 10), probably reflecting increased amino acid and sugar 
availability. Replenishment of DMEM alongside IL-36γ stimulation does not lead to 
a statistically significant change, although a downward trend may be apparent 
(p=0.0857) (Figure 11A). As expected FCS stimulation causes upregulation of pS6, 
observable at 30 minutes and continuing up to 24 hours (Figure 11A). However, 
unlike in serum-starved conditions, when treated with FCS and IL-36γ there is a 
statistically insignificant initial increase in pS6 at 30 minutes. At 24 hours there is a 
downregulation of pS6 signalling (p=0.026) (Figure 11A, B).  
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Figure 10. IL-36 reduces AKT phosphorylation and alters pS6 signalling. HFFs were serum starved 
for 16 hours, before media replacement, or treatment with 10% FCS or 100ng/ml IL-36γ. A 
representative western blot showing pAKTser473, pAKTthr308 and pS6RP signalling at 30min, 6 
and 24-hour timepoints.  
Figure 10: IL-36 reduces AKT phosphorylation and alters pS6 signalling. 
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Figure 11. IL-36 reduces AKT phosphorylation and alters pS6 signalling.  HFFs were serum starved 
for 16 hours, before media replacement, or treatment with 10% FCS or 100ng/ml IL-36γ. 
Densitometric analysis was performed on western blots for (A + B) pS6RP/S6RP, (C) pAKTthr308/AKT, 
and (D) pAKTser473/AKT. Panel B represents 24 hours following stimulation. Panels (C + D) represent 
30 mins following stimulation. Serum starved conditions for pAKT have two biological repeats, and all 
other samples have between three and nine.  
Figure 11: IL-36 reduces AKT phosphorylation and alters pS6 signalling (densitometric analysis) 
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3.6 mTOR inhibition increases IL-8 induction by IL-36γ 
 
Rapamycin is (at 50nM) a specific inhibitor of mTOR1 activity, via an indirect 
mechanism (Foster & Toschi 2009). Rapamycin was used to demonstrate whether 
mTOR modulation results in alteration of inflammatory cytokine signalling from IL-
36. This was measured by qRT-PCR of IL-1β and IL-8 mRNA, and IL-8 was measured 
on a protein level by ELISA. Again, western blot for S6 was performed in order to 
measure mTORC1 activity. 
Diminution of detectable pS6 signalling occurs following treatment with rapamycin 
(p=0.0387) (Figure 12). With regards to IL-8 mRNA, an induction is observable with 
rapamycin treatment (p<0.0001), and a larger induction when treated with IL-36γ 
and rapamycin, compared to IL-36 alone (p<0.0001) (Figure 13A). Upregulation of 
IL-8 by rapamycin was also apparent when measured by ELISA (p=0.0028), as well 
as enhanced IL-8 induction by IL-36γ during mTOR inhibition (p<0.0001) (Figure 
13B).   
A non-significant trend towards upregulation was observed for IL-1β (p=0.1759), 
and it does appear there is an increase in variance in IL-36γ and rapamycin-treated 
cells (see Figure 13C). 
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Figure 12. Rapamycin reduces mTOR signalling. HFFs were serum starved overnight, pre-treated 
with 50nM rapamycin, then stimulated with 10% FCS and 100ng/ml IL-36γ. n = 3. Representative 
western blot (A) and densitometric analysis (B) show complete reduction in pS6/S6. 
Figure 12: Rapamycin reduces mTOR signalling 
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Figure 13. mTOR inhibition enhances effects of IL-36. HFFs were serum starved overnight, pre-
treated with 50nM rapamycin, then stimulated with 10% FCS and 100ng/ml IL-36γ. n = 3. 
Rapamycin upregulates IL-8 and increases IL-36 induced upregulation of IL-8 when measured by 
qRT-PCR (A) and ELISA (B). Rapamycin also increases upregulation of IL-1β on a mRNA level (C). 
Sample mRNA is normalised to GAPDH. Significance was determined via one-way ANOVA 
Figure 13: mTOR inhibition enhances effects of IL-36 
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3.7 TSC knockdown activates mTOR but does not alter 
IL-8 induction by IL-36γ 
 
To determine if a downregulation of proinflammatory cytokine signalling would be 
observed with mTOR upregulation, reciprocal to rapamycin treatment, TSC 
knockdown was performed. The TSC complex is a negative regulator of mTOR 
activity, TSC1 knockdown was used to induce mTOR signalling in serum depleted 
conditions (Laplante and Sabatini 2012). Western blot for S6 was performed to 
measure mTORC1 activity, and this was followed by ELISA for IL-8 to determine a 
functional effect on cytokine induction by IL-36, following TSC1 knockdown. Serum 
starvation was used in this experiment so that pS6 would be observable, and not 
obscured by FCS induced mTORC1 activation.  
Indeed, TSC1 knockdown did lead to increased pS6 signalling (p=0.0300) (Figure 14A 
+ B). However, this did not translate to any observable alteration in IL-8 induction 
by IL-36γ. Although generally IL-8 was detected at much lower levels in samples 
that had undergone transfection with either siNTC or siTSC (Figure 15), this level of 
induction is comparable to IL-8 induction in serum starved cells, where it was also 
found to be insignificant.  
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Figure 14. TSC knockdown induces mTOR activity. HFFs were transfected with 50nM siNTC or 
siTSC, and following 24h placed in FCS free conditions, and stimulated with 100ng/ml IL-36γ. 
n=3. Western blot (A) and densitometric analysis (B) demonstrate TSC knockdown results in 
upregulation of pS6/S6. Significance was determined via one-way ANOVA 
Figure 14 TSC knockdown induces mTOR activity. 
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Figure 15. TSC knockdown does not alter IL-8 induction by IL-36. HFFs were transfected with 
50nM siNTC or siTSC, and following 24h placed in FCS free conditions, and stimulated with 
100ng/ml IL-36γ. n=3. ELISA demonstrates that transfection with siTSC does not alter IL-8 
production, nor does it alter IL-36 induced IL-8 production. Significance was determined via 
one-way ANOVA 
Figure 15: TSC knockdown does not alter IL-8 induction by IL-36. 
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4. Discussion 
4.1 Summary 
This project aimed to determine the proinflammatory effects of IL-36γ on stromal 
cells, before exploring the effects of IL-36γ on signal transduction, and testing if 
mTOR modulation affects IL-36 induced cytokine production. To achieve this, we 
assessed signal transduction downstream of IL-36 and identified a negative role for 
IL-36γ in AKT activity, possibly due to mTOR induction via an independent 
mechanism. We identified that NFκB is necessary for cytokine induction in dermal 
fibroblasts by IL-36γ. Finally, it was demonstrated that mTORC1 negatively regulates 
IL-8 induction in fibroblasts, however we were unable to demonstrate an effect 
from upregulation of mTOR using RNAi.  
 
 
 
 
Figure 16. Synopsis of crosstalk between IL-36 signalling and mTOR in HFFs 
Figure 16: Synopsis of crosstalk between IL-36 signalling and mTOR in HFFs 
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4.2 The effects of IL-36γ on signal transduction  
 
There are multiple explanations for the downregulation in AKT activity observable 
at 30 minutes. It could be suggested that there is brief phosphorylation of AKT 
followed by a compensatory downregulation, as in human lung fibroblasts (HLFs) 
AKT phosphorylation due to IL-36γ occurs as quickly as 5 minutes following 
stimulation.  However, this effect was shown to be sustained for at least an hour 
(Zhang et al. 2017). In mouse embryonic fibroblasts (MEFs) TNFα induced AKT 
activation was at its maximum at 30 minutes post stimulation (Ghosh et al. 2006). 
Additionally, no induction of AKT was seen in serum starved conditions.  
 
Activation of AKT by inflammatory signalling has been demonstrated to be a cell 
type specific phenomenon (Ozes et al. 2001; Delhase et al. 2000). In the context of 
human fibroblasts, multiple kinases such as ERK, p38 and c-Jun N-Terminal kinase 
(JNK) have been demonstrated to modulate mTOR through an AKT independent 
mechanisms  (Li et al. 2003; Ma et al. 2005). In multiple breast cancer lines IKK beta 
(a major upstream regulator of NFκB) has been shown to activate mTOR via the TSC 
complex, which has a IKKβ target site at Ser511  (Lee et al. 2007).  
 
Therefore, a better explanation for the changes in AKT would be that they are due 
to mTOR activation via an AKT independent mechanism, because of the well 
described compensatory downregulation mechanisms of AKT and mTORC2 
following mTORC1 activation (Laplante & Sabatini 2012).  
 
A clear limitation to the interpretation of signalling events in IL-36γ stimulation, is 
the lack of statistical significance in the quantification of western blot data for S6 at 
30 minutes. Although this was not deemed significant by ANOVA, because of 
variation in degrees of induction, an upregulation was observable in all three 
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repeats of this experiment. Due to time constraints it was not possible to perform 
more repeats of this experiment, and this should be done before a firm association 
between mTOR activation and IL-36 signalling is made. Conditional on this, AKT 
could be either pharmaceutically inhibited or through RNAi to see if the effects of 
IL-36 on mTOR are preserved. Inhibition of other targets such as ERK, p38, JNK and 
IKKβ could be performed to elucidate which kinases are necessary for mTOR 
activation. Knockdown of TSC1 or 2 would reveal if this is a TSC dependant 
mechanism, as found in other cell types  (Lee et al. 2007).  Unfortunately, due to 
time constraints assessing knockdown of TSC1 on mTOR activation 30 minutes post 
stimulation with IL-36γ was not performed.  
 
BAY-11 treatment eliminated basal IL-8 and its induction by IL-36γ suggesting this is 
mediated by NFκB. Although it has also been shown that BAY-11 has effects 
independent of NFκB inhibition with inhibitory effects on inflammasome activity 
(Juliana et al. 2010) as well as indirect suppression of MAPK activation pathways 
(Lee et al. 2012). Verification that IL-36γ signals through NFκB would be supported 
by blotting for phospho-NFκB, however we unable to successfully do this. These 
findings agree with research performed on synovial fibroblasts, where NFκB 
activation is necessary for IL-36γ transduction (Frey et al. 2013). However, our 
findings contrast to those of Zhang et al, where it was demonstrated that BAY-11 
treatment does not alter IL-8 release by any of the IL-36 cytokines in human lung 
fibroblasts, or human bronchial epithelial cells.  (Zhang et al. 2017)    
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4.3 Upregulation of miR-21 
 
miR-21 was shown to be induced at 6 hours following IL-36 stimulation. In 
fibroblasts miR-21 alters fibroblast expression of matrix metalloproteinases 
production, an enzyme with pathologic significance in psoriasis (Gabriely et al. 
2008).  In macrophages miR-21 interferes with TNFα production through a 
mechanism involving Phosphatase and tensin homolog (PTEN), a phosphatase 
which acts as a key negative regulator of the PI3K/AKT/mTOR axis (Das et al. 2014). 
Elsewhere, lipopolysaccharide (LPS) has been demonstrated to upregulate miR-21 
in fibroblasts at 4 hours, with no substantial increase between 4 and 8 hours 
(Sheedy et al. 2010).   Although the magnitude of effect on miR-21 was small, this is 
a very highly expressed microRNA, and stimulation with Angiopoietin 1  
(ANG1), a strong mTOR inducer, only results in a 1.2-1.5 fold induction. (Warner et 
al. 2016). The role of miR-21 in dermal psoriatic fibroblasts should be investigated 
more deeply. Due to time constraints later time points were not performed, but 
may have revealed changes in the other miRNA that were probed for.  
 
4.4 Effects of mTOR modulation on cytokine induction 
 
To assess if modulation of mTOR impacts on cytokine expression, cells were treated 
in several ways. Firstly, it was shown that FCS upregulates mTOR activity. Induction 
of IL-8 by IL-36 was increased in the presence of FCS, this was demonstrated by 
both qRT-PCR and ELISA, with FCS also leading to some induction in the absence of 
IL-36γ and similar effects were observed in IL-1β mRNA.  
 
There are a number of significant limitations when using FCS to induce mTOR 
activity, as it is a variable natural product containing many undefined proteins, 
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including multiple growth factors, it has potential to variably alter cytokine profiles 
of treated cells, and its effects are broad with effects far beyond that of mTOR 
activation, as although mTOR is downstream of many growth factor receptors, it 
does not exist in isolation as their only effector (Hayashi et al. 1978; Saxton and 
Sabatini 2017). When assessing subtle signalling dynamics or cytokine changes, and 
where serum starvation is inappropriate, it would be beneficial to use a chemically 
defined media.  
 
Furthermore, although phenotypically similar, in human foreskin fibroblasts, 
mTORC1 inhibition and serum starvation leads to divergent and unique 
transcriptomic profiles (Gillespie et al. 2015). Further dissection reveals that 
following rapamycin treatment, cytokine related pathways were amongst the most 
highly altered genes in the array, especially IL-8 which was confirmed by both qRT-
PCR and ELISA (Gillespie et al. 2015). This suggests that using serum is perhaps not 
the best tool for assessing the contribution of mTOR to inflammatory signalling.  
 
In the dose range used, rapamycin is a selective inhibitor of mTORC1 (Foster & 
Toschi 2009). Rapamycin treatment leads to an increase in IL-8 expression, as well 
as augmented induction by IL-36γ, on both a transcriptional and a protein level. It is 
possible that upregulation of inflammatory cytokines by mTORC1 inhibition is not 
limited to IL-8, as although alone rapamycin does not induce IL-1β, there was a non-
statistically significant trend towards the upregulation IL-36γ mediated expression. 
Due to time constraints this was unable to be repeated, and for the same reason IL-
1β was not measured on a protein level, however this may be a valuable avenue in 
future work.  
  
This suggests that mTORC1 has a negative role in the regulation of NFκB. The 
negative role of mTOR in proinflammatory cytokine expression by fibroblasts has 
been demonstrated elsewhere where rapamycin has been shown to enhance TNFα 
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stimulated production of both IL-6 and IL-8, in human orbital fibroblasts (Lee et al. 
2013)  However, it cannot be said explicitly if this is directly due to mTORC1, as it is 
well documented that rapamycin treatment upregulates both mTORC2 activity and 
components of pathway above mTORC1 such as AKT and effects seen in rapamycin 
treatment may reflect the upregulation of other pathways. As S6K1 also inhibits 
MAPKs (Carracedo et al. 2008),  the dynamics of other signalling pathways, such as 
ERK, p38 or JNK, in rapamycin treated HFFs needs to be elicited. Indeed activator 
protein 1 (AP-1), the putative target of JNK is activated in IL-36 signalling and has 
been demonstrated to be altered in some instances of rapamycin treatment 
(Weichhart et al. 2008).  
 
The clinical implications of this must be interpreted with caution because prolonged 
exposure to rapamycin has been shown to result in impaired mTORC2 signalling in 
some cell lines, through a mechanism where free mTOR becomes bound and 
unable to form functional mTORC2 complexes  (Sarbassov et al. 2006). This is 
significant as in its clinical context patients are often exposed to long treatment 
regimes. In cell culture, this is something that could be investigated by utilising 
prolonged treatment with rapamycin or by use of mTORC1/mTORC2 dual inhibitors.  
 
Additionally, rapamycin does not inhibit all of the functions of mTORC1, as although 
phosphorylation of S6 is reduced, inhibition of 4E-BP1 may be spared (Choo et al. 
2008). It could be explored further if complete mTOR inhibition results in a different 
effect on inflammatory signalling.   
 
RNAi of TSC1 was successful with regards to the fact mTOR signalling was induced, 
despite a background of serum-starvation, however this did not translate into any 
measurable effect on IL-8 induction by IL-36γ. In contrast, it has been reported 
elsewhere that activation of mTOR by loss of the inhibitory TSC1/TSC2 function 
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resulted in decreased NFκB activity in murine embryonic fibroblasts (Ghosh et al. 
2006).  
This may either reflect a difference between murine and human fibroblasts or may 
reflect altered signalling dynamics in stable knockout. Additionally, we utilised 
serum starvation, so phosphorylation of S6 would be readily observable, and to 
avoid some of the limitations of FCS already discussed. This may possibly indicate 
that some degree of growth factor signalling may be necessary for mTOR to 
regulate NFκB. Another interpretation could be that since most of the experiments 
were done on a background of stable TSC2 knockout, the regulation of NFKB is 
specific to TSC2 rather than the functioning of the heterodimeric complex. 
Alternatively, a difference in IL-8 induction may simply have been very small, since 
in serum starved conditions, induction of IL-8 by IL-36γ is less substantial compared 
to in serum replete conditions, indeed in previous experiments the induction of IL-8 
by IL-36γ during serum starvation has not been statistically significant.  
 
4.5 Other implications of findings  
 
mTORC1 is sensitive to modulation by amino acids particularly glutamine, leucine, 
and arginine (Jewell et al. 2013; Rebsamen & Superti-Furga 2016). This is significant 
for future investigations as the effect of rapamycin treatment may reflect a role for 
dermal fibroblasts in altering/coordinating the local inflammatory 
microenvironment to nutrient availability and could be relatively easily be studied 
through the restriction and introduction of amino acids. Indeed, this has been 
performed in fibroblast-like-synoviocytes, an effector cell in rheumatoid arthritis, 
where it was revealed that amino acid restriction leads to upregulation of IL-8, 
through a mTOR dependant mechanism (Karonitsch et al. 2018). 
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Pharmaceutical inhibition of mTOR through rapamycin has been shown to have 
rather limited clinical efficacy in psoriatic disease, despite its promise as potent 
immunosuppressive agents (Ormerod et al. 2005). Using an imiquimod induced 
psoriasis mouse model, rapamycin successfully reduced disease severity. With 
reduction in skin thickness and a marked reduction in neovascularization in the skin. 
It was speculated that these anti-psoriatic effects were driven by mTORC1 inhibition 
enhancing differentiation of keratinocytes, and possibly reducing their 
proinflammatory cytokine output (Bürger et al. 2017). This is accompanied by the 
well documented effects of rapamycin on T cells (Sehgal & Bansbach 1993). 
However, it has been shown elsewhere that in innate immune cells such as 
monocytes and dendritic cells, that mTOR inhibition results in an excessively 
proinflammatory phenotype (Weichhart et al. 2008), it has been shown here that 
the induction of inflammatory associated cytokines by IL-36 is enhanced by 
rapamycin treatment in primary dermal fibroblasts, which may somewhat explain 
residual psoriatic symptoms following mTOR inhibition. 
 
The complexities of mTOR having a pleiotropic role in inflammatory responses are 
illustrated by events such as interstitial pneumonitis, occurring in patients receiving 
rapamycin as part of a post-transplant immunosuppression regimen (Singer et al. 
2000). This work could suggest that some portion of this effect may be attributable 
to enhancement induction of proinflammatory cytokines in stromal cells of affected 
individuals. 
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4.6 Further limitations  
 
Regulation of the IL-36 receptor by either FCS or IL-36γ was not statistically 
significant and was only assessed on a mRNA level. However, the dynamics of 
receptor expression on a functional level would need to be assessed over a greater 
time frame, and through a modality which can appreciate changes in protein, and 
cell surface expression, since regulation may occur on a non-transcriptional level. 
 
The degree of induction as measured by qRT-PCR and ELISA differed. Induction of 
cytokines occurs at multiple levels, both transcriptionally and post transcriptionally 
via mechanisms such as affecting the stability of mRNA, or the proteins may require 
post translational processing for full functional activity as is the case with both IL-1β 
and IL-36γ (Rubartelli et al. 1993; Ainscough et al. 2017). Furthermore secreted 
cytokines may interact with in vitro cultured cells, resulting in their removal from 
supernatant either by degradation or consumption.  Treatments such as FCS, 
rapamycin and siTSC may alter this uptake (Verfaillie et al. 2001). Additionally IL-8 is 
not the only readout of fibroblast activation, as activation is more nuanced than a 
global activation.  
 
Due to the functional diversity observable in fibroblasts, HFFs may not be entirely 
representative of fibroblasts found in the psoriatic environment, because of both 
the location of their derivation and disease state. This is exemplified by the 
abolishment of IL-8 induction in our HFFs treated with BAY-11, and IL-36γ, when in 
HLFs this was shown to have no effect (Zhang et al. 2017). as well as increased IL-8 
induction by TNF in lesional fibroblasts compared to non-involved skin (Zalewska et 
al. 2006).  
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4.7 Future Work 
 
These findings help explain the failure of rapalogs, which were initially seen as 
promising therapeutic agents, in the treatment of psoriatic disease. Future work 
could investigate more complete mTORC1 inhibition, or dual inhibition of both 
mTOR compounds.  
In order to better define a mechanism for the alteration of AKT/mTOR signalling 
observed here, we suggest the use of inhibitors for MAPKs, PI3K, and NF-κB 
signalling components. It would also be worthwhile investigating the effects of 
mTOR modulation on other cytokines, as well as alterations in ECM production, 
which have been shown to alter both angiogenesis and immune cell function in the 
psoriatic environment 
To investigate whether fibroblasts have the potential to function as nutrient-
sensing sentinel cells we propose modulating mTOR activity through amino acid 
availability. This could be relatively easily achieved through the restriction and 
introduction of amino acids associated with mTORC1 activation. 
Finally, due to the limitations of using HFFs as a model for fibroblasts found in the 
psoriatic environment, future work should confirm whether IL-36 initiates a change 
in AKT/mTOR signalling in lesional fibroblasts. This should be followed by a direct 
comparison between lesional and non-lesional samples of dermal fibroblasts.  
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5 Conclusions 
 
This project aimed to investigate signal transduction downstream of IL-36γ, in 
primary dermal fibroblasts, with a focus on the mTOR axis. In addition to the 
upregulation of proinflammatory cytokines, we revealed a negative role for IL-36γ 
in AKT activation, which could be attributed to feedback loops following AKT 
independent activation of mTOR signalling.  
We demonstrated that NFκB is necessary for cytokine induction by IL-36γ.  
Furthermore, we established that mTOR modulation effects induction of 
proinflammatory cytokines by IL-36γ. Inhibition of mTORC1, through treatment 
with rapamycin, resulted in an upregulation of IL-8, however, we were unable to 
demonstrate a clear reciprocal effect resulting from the upregulation of mTOR via 
RNAi.  
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Appendices 
Solution Reagents 
RIPA buffer 150mM NaCl 
10mM Tris HCl 
0.1% (w/v) SDS 
0.1% (v/v) Triton X1000 
1% (w/v) Sodium Deoxychlorate 
5mM EDTA 
Sample Buffer 250nM Tris HCL pH 6.8 
8% (w/v) SDS 
10% (w/v) Glycerol 
5% (v/v) βME 
0.05% (w/v) Bromophenol Blue 
Stacking Gel ddH2O 4.1ml 
30% Acrylamide 1mL 
1.5M Tris (pH 6.8) 750μl 
10% SDS 60μl 
10% APS 60μl 
TEMED 6μL 
Resolving Gel ddH2O 6ml 
30% Acrylamide 8mL 
1.5M Tris (pH 8.8) 5mL 
10% SDS 200μl 
10% APS 200μl 
TEMED 8μL 
10X TBS 12.2g Tris HCl 
87.65 NaCl 
1L ddH20 
pH 8 Western Blot; pH 7.4 ELISA 
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Western Blot TBS/T (1%) 100ml 10X TBS pH 8.0 
900ml ddH2O 
1ml Tween-20 
ELISA TBS/T (0.5%) 100ml 10X TBS pH 7.4 
900ml ddH2O 
0.5ml Tween-20 
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Abbreviations 
 
4E-BP1: Eukaryotic translation initiation factor 4E-binding protein 1 
AGO: Argonaute protein  
AKT: Protein kinase B 
ANOVA: Analysis of variance 
ATP: Adenosine Triphosphate 
BCA: bicinchoninic acid  
BSA: bovine serum albumin 
CT: cycle threshold 
CXC10: C-X-C motif chemokine 10 
DGCR8: DiGeorge syndrome critical region 8 
DMEM: Dulbecco’s modified Eagle’s Medium  
DNA: Deoxyribose nucleic acid 
ECL: Enhanced chemiluminescence 
ECM: extracellular matrix 
ECM: Extracellular matrix 
ELISA: enzyme-linked immunosorbent assay 
ERK: extracellular signal-regulated kinase 
FCS: Foetal calf serum 
FLS: Fibroblast-like synoviocyte 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase  
GDP: Guanosine diphosphate 
GTP: Guanosine triphosphate 
HFF: Human Foreskin Fibroblasts 
HIV: Human immunodeficiency virus 
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HRP: Horseradish peroxidase 
ICAM: Intercellular Adhesion Molecule  
IFN-γ: Interferon gamma 
IKK: IκB Kinase 
IL: Interleukin 
IL-1Rl2: Interleukin 1 Receptor like 2 
IL-36R: Interleukin 36 Receptor 
IRAK1: Interleukin-1 receptor-associated kinase 1 
JNK: c-Jun N-Terminal kinase 
LL-37: cathelicidin 
MAPK: Mitogen-activated protein kinases 
MEF: Mouse embryonic fibroblasts 
mRNA: messenger RNA 
mTOR: mechanistic Target of Rapamycin 
NF-ĸB: nuclear factor kappa-light-chain-enhancer of activated B cell 
NTC: non-targeting control 
PACT: Protein Activator of PKR 
PACT: Protein activator of PKR 
PASI: Psoriasis associated severity index  
PBS: Phosphate buffered saline 
PDGFR: Platelet-derived growth factor receptor 
PTEN: Phosphatase and tensin homolog 
PVDF: Polyvinylidene fluoride 
qRT-PCR: Reverse transcription polymerase chain reaction 
RBD: double-stranded RNA-binding domains 
RIPA: Radioimmunoprecipitation assay buffer 
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RISC: RNA induced silencing complex 
RNA: double-stranded RNA 
RNAi: RNA interference 
S100A7: psoriasin 
SDS: Sodium dodecyl sulphate 
SEM: Standard error of the mean 
SLE: Systemic lupus erythematosus 
STAT3: Signal transducer and activator of transcription 3  
TBS: Tris Buffered Saline 
TCR: T Cell Receptor 
TLR: Toll like receptor 
TNFα: Tumour necrosis factor 
TRAF6: Tumour necrosis factor receptor (TNFR)-associated factor 6 
TRBP: HIV-1 TAR RNA binding protein 
TSC: Tuberous Sclerosis Complex 
TSC: Tuberous Sclerosis complex 
UTR: Untranslated Region 
VCAM: Vascular cell adhesion protein 
VEGF: Vascular endothelial growth factor 
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